MFLRC
Licensing and regulatory updates from our consultants.
October 25, 2026 · GMP
FDA's warning letter to Medline over recurring Bacillus cereus in finished product is a lesson in objectionable microorganisms, contamination control and CAPA effectiveness. Here is what it means for Canadian GMP sites.
#Microbial Contamination
By Mussarat Fatima
October 25, 2026 · Food and Beverages
On 23 October 2026 FDA proposed cadmium action levels for baby food and released draft Chapter 12 on controlling chemical hazards. Here is what Canadian food exporters should do now.
#Heavy Metals
By Mussarat Fatima
October 24, 2026 · GMP
Germany's medical cannabis market keeps growing while Canada's share slips. Here is why EU-GMP certification, not price, is the last real moat, and how to protect your access before certified competitors take the shelf.
#Cannabis
By Mussarat Fatima
October 24, 2026 · Medical Device
The FDA warning letter to Olympus named six manufacturing sites in three countries and cited the same CAPA failure at every one. Here is what it means for multi-site device makers, importers and Canadian MDEL holders, and how to build the corporate CAPA oversight inspectors now expect.
#FDA
By Mussarat Fatima
October 23, 2026 · Pharmaceuticals
FDA cited SCA Pharmaceuticals, a 503B outsourcing facility, for ISO 5 areas without routine certification or dynamic airflow visualization. Here is what cleanroom certification really means and how to prove yours would survive an inspection.
#Aseptic Processing
By Mussarat Fatima
October 23, 2026 · Pharmaceuticals
FDA cited Baxter's Round Lake plant after cephalosporin kept crossing a sealed wall. Here is what the warning letter means for Canadian and exporting drug makers, and how to prove your segregation, flow and detection controls actually work.
#Cross-Contamination
By Mussarat Fatima
October 22, 2026 · Natural Health Products
Health Canada's Bulletin No. 13 lets natural health product licence holders defer monograph-related label updates, yet the Product Facts table requirement and the 21 June 2028 compliance date still stand. Here is what changed, what did not, and how to plan your relabelling.
#Natural Health Products
By Mussarat Fatima
October 22, 2026 · Pharmaceuticals
FDA's warning letter to Curia New York cites thousands of unexplained chromatography injections, shared logins and original records in shred bins. This is the data-integrity checklist Canadian API and pharmaceutical exporters should run before an inspector arrives.
#Data Integrity
By Mussarat Fatima
October 21, 2026 · Quality Assurance
A failing result is an event. A failing investigation is a finding. Here is how to investigate a deviation or out-of-specification result in a way that satisfies Health Canada, from the two-phase OOS model to root cause, CAPA and the records that hold up.
#Out-of-Specification
By Mussarat Fatima
October 21, 2026 · GMP
When Teva and a repackager recalled the same drug for foreign tablets eight days apart, they exposed how a source defect travels downstream. Here are the incoming inspection, line clearance, reconciliation and recall controls that catch it under Canadian GMP.
#Drug Establishment Licence
By Mussarat Fatima
October 20, 2026 · Pharmaceuticals
FDA's October 2026 Lovelace warning letter found nonclinical final reports that did not match the raw data. Here is what 21 CFR Part 58 requires, why FDA rejected the fix, and how Canadian sponsors should audit the CROs they rely on.
#Good Laboratory Practice
By Mussarat Fatima
October 20, 2026 · Pharmaceuticals
When a warning letter forces a production stop, restarting is not automatic. Using FDA's October 2026 Silgan letter, here is the evidence package, the six-system audit and the 211.34 consultant role that get a firm back to manufacturing.
#FDA
By Mussarat Fatima
October 19, 2026 · Pharmaceuticals
The Aleve Type III recall was caused by returned product going back into saleable inventory, not a manufacturing defect. A practical returns and disposition control guide for Canadian pharma, NHP, and cannabis distributors.
#Returned Goods
By Mussarat Fatima
October 19, 2026 · Pharmaceuticals
FDA's warning letter to Eurofins SF Analytical Laboratories shows how a contract lab's microbial data failures become the sponsor's adulteration problem. A practical oversight guide for Canadian drug and NHP exporters.
#Contract Laboratory
By Mussarat Fatima
October 17, 2026 · Quality Assurance
What an Annual Product Quality Review must cover under Health Canada GUI-0001, EU GMP Chapter 1, FDA 21 CFR 211.180(e) and ICH Q7, who must do one and how often, and how to build an APQR report that survives inspection.
#Annual Product Quality Review (APQR)
By Mussarat Fatima
October 17, 2026 · Quality Assurance
How to receive, investigate, trend and escalate product complaints under Canadian GMP, including the 15-day adverse reaction clock for drugs, natural health products and cannabis, and when a complaint becomes a recall.
#Complaint Handling
By Mussarat Fatima
October 16, 2026 · GMP
A practical guide to GMP change control: how to classify a change by risk, assess its impact with quality risk management, and close it with an effectiveness review, mapped to ICH Q10, Annex 15, GUI-0001 and the FDA rules.
#Change Control
By Mussarat Fatima
October 16, 2026 · Quality Assurance
A cannabis QAP must assure product quality before sale, investigate complaints, and act on risk under section 19. Here are the QAP's duties, authority, qualifications, the 2026 changes, and the inspection findings that keep landing on the quality unit.
#QAP (Quality Assurance Person)
By Mussarat Fatima
October 15, 2026 · Good Production Practices
A June 2026 Health Canada recall involved a 3 x 0.5 g pre-roll packaged as a single 1 g joint. Here are the Cannabis Regulations labelling rules, the net-weight tolerance limits, and the packaging line-clearance controls that prevent these recalls.
#Cannabis
By Mussarat Fatima
October 15, 2026 · Pharmaceuticals
Health Canada's July 2026 safety brief warns that carbamazepine and oxcarbazepine oral suspensions can expose neonates and young children to harmful propylene glycol. Here is how to build an excipient risk assessment that holds up under inspection.
#Pediatric Drugs
By Mussarat Fatima
October 14, 2026 · Biologics
On 13 October 2026 FDA finalized its Q&A guidance on postapproval manufacturing changes to biosimilar and interchangeable biosimilar products. Here is what changed from the draft, how comparability works under ICH Q5E, and the change-control steps sponsors should take before filing.
#Biosimilars
By Mussarat Fatima
October 13, 2026 · Regulatory Affairs
A brand licence puts your name on a UK shelf, but it does not move the regulatory burden. Here is how the MHRA, Home Office and Human Medicines rules allocate responsibility, and the contract traps that create exposure for a Canadian producer.
#Cannabis
By Mussarat Fatima
October 13, 2026 · GMP
A shallow batch failure investigation is one of the fastest routes to an FDA 483 or warning letter, as a July 2026 OOS-averaging case shows. Here is what 21 CFR 211.192 requires, how it connects to out-of-specification results, and how to build an investigation that closes.
#FDA
By Mussarat Fatima
October 12, 2026 · Regulatory Affairs
SOR/2025-242, Canada's new Controlled Substances Regulations, came into force on 1 October 2026. Monthly reporting, a unified dealer's licence, new ministerial powers, and what manufacturers and dealers must do now that the framework is live.
#SOR/2025-242
By Mussarat Fatima
October 12, 2026 · Medical Device
On 25 September 2026 the FDA released a 50-page draft guidance on premarket submissions for robotically assisted surgical devices. Here is what it expects, and what Canadian device makers should do before the 24 November comment deadline.
#Medical Devices
By Mussarat Fatima
October 11, 2026 · License
Cannabis licence revocations now outpace new licences in Canada, and most are at the holder's request. Here is why, and how licensed producers keep a licence in good standing.
#Cannabis
By Mussarat Fatima
October 11, 2026 · Natural Health Products
FDA's 1 October 2026 warning letters treat homeopathic and OTC products with disease claims as unapproved new drugs, and named Amazon as a distributor. Here is what Canadian exporters must fix.
#FDA
By Mussarat Fatima
October 10, 2026 · Good Production Practices
Health Canada ran 902 cannabis inspections in 2025 to 2026 and issued 29 non-compliant reports. The same documentation, GPP and assigned-responsibility findings recur. Here is what the data shows and how to prepare.
#Cannabis
By Mussarat Fatima
October 10, 2026 · Compliance
FDA says it intends to proactively publish redacted Form 483s and more inspection reports. For Canadian exporters, a routine inspection observation could soon be public. Here is what changes and how to get ready.
#FDA
By Mussarat Fatima
October 9, 2026 · Medical Device
A recent GORE VIABAHN recall was scoped to specific catalogue, lot and serial numbers. For Canadian device importers and distributors, that is a test of traceability. Here is what the Medical Devices Regulations require, and why Canada's distribution records, not a UDI database, do the heavy lifting.
#Medical Devices
By Mussarat Fatima
October 9, 2026 · Cosmetics and Personal Care
On 3 October 2026, Environment and Climate Change Canada and Health Canada began developing CEPA criteria to identify carcinogenic, mutagenic and reproductive-toxic (CMR) substances. Comments close 2 December 2026. Here is what cosmetic, biocide, NHP and formulation teams should check now.
#CEPA
By Mussarat Fatima
October 8, 2026 · Cosmetics and Personal Care
MoCRA reshaped FDA oversight of cosmetics. Here is what Canadian cosmetic exporters must do now: register facilities, list products, appoint a U.S. agent, keep safety records, and prepare for the GMP and fragrance allergen rules.
#Cosmetics Canada
By Mussarat Fatima
October 8, 2026 · Natural Health Products
Health Canada's 23 April 2026 notice reclassifies sports electrolyte products as foods. Learn what is in scope, what the food framework requires, and how NPN holders should plan the move before the 31 December 2027 target.
#Supplemented Foods
By Mussarat Fatima
October 7, 2026 · Pharmaceuticals
On 28 September 2026 the Council of the EU adopted its position on the long awaited pharmaceutical package. It is not law yet, but the reform rewrites the exclusivity math and adds supply obligations that Canadian sponsors selling into Europe need to plan for now.
#EU Pharmaceutical Package
By Mussarat Fatima
October 7, 2026 · Regulatory Affairs
The Netherlands is ending state run medical cannabis exports by the close of 2026. Here is what the Dutch retreat means for European supply, and how Canadian producers with EU-GMP and GACP certification can be ready to fill the gap.
#Cannabis
By Mussarat Fatima
October 6, 2026 · Regulatory Affairs
A single, verified calendar of the regulatory deadlines Canadian licence holders face in Q4 2026, across medical devices, drugs, clinical trials, cannabis and provincial programmes, from 13 October to 31 December, with the action each one calls for.
#Regulatory Deadlines
By Mussarat Fatima
October 6, 2026 · Medical Device
Health Canada's recall of Innovacon hCG pregnancy tests for possible false positives is a case study in IVD classification, performance claims, labelling and the problem-reporting and recall clocks every Canadian device licence holder must meet.
#Medical Devices
By Mussarat Fatima
October 5, 2026 · Medical Device
FDA device establishment registration for FY2027 is open 1 October to 31 December. Canadian exporters: the $13,785 fee, the US agent rule, device listing, and how to renew without a lapse.
#FDA
By Mussarat Fatima
October 5, 2026 · Medical Device
Health Canada medical device licences for Class II, III and IV devices must be renewed before 1 November. Here is what section 43 requires, the 2026 fee, and how to avoid licence cancellation.
#Medical Device Licence
By Mussarat Fatima
October 3, 2026 · Regulatory Affairs
A GAO report on scheduling process gaps led the DEA's chief judge to pause the marijuana rescheduling hearing on 29 September 2026, with responses due 13 October. Here is what the delay, the 280E question and a possible Schedule II outcome mean for Canadian licensed producers.
#Controlled Substances
By Mussarat Fatima
October 3, 2026 · Food and Beverages
A single contaminated alfalfa seed lot caused a multi-pathogen outbreak across 16 US states. For Canadian growers, sprouters and importers, it is a clear lesson in where sprout contamination begins and how a preventive control plan should control it at the seed.
#Sprouts
By Mussarat Fatima
October 2, 2026 · Pharmaceuticals
Storage and distribution are where many GMP findings and recalls begin. Here is what 21 CFR Part 211 and Health Canada's GUI-0001 require for quarantine, storage conditions, stock rotation and lot traceability, and how to prove control before an inspection.
#Warehouse Controls
By Mussarat Fatima
October 2, 2026 · Pharmaceuticals
Health Canada's DEL Phase 2 will ease the annual licence review, add new terms, conditions and suspension powers, and move to risk-based oversight. Here is what changes and how to prepare your site now.
#Drug Establishment Licence
By Mussarat Fatima
September 30, 2026 · Food and Beverages
A CFIA recall pulled a cheese contaminated with Staphylococcus aureus. The real lesson is that its toxin is heat-stable, so cooking cannot save a product once the bacteria have grown. Here is what your PCP must control.
#Preventive Control Plan
By Mussarat Fatima
September 30, 2026 · Regulatory Affairs
Canada's UK medical cannabis opening is here. Learn the Health Canada export permit, UK Home Office import licence, MHRA GMP expectations and the buyer documentation you need before you ship.
#Cannabis
By Mussarat Fatima
September 29, 2026 · Natural Health Products
A New Roots probiotic was recalled because its no dairy claim was false, it contains bovine colostrum. Here is what NHP claim verification and allergen controls must prove before a label is printed.
#Natural Health Products
By Mussarat Fatima
September 29, 2026 · Natural Health Products
FDA cited 72.5 percent of foreign dietary supplement sites in FY2025. Here are the 21 CFR 111 specification, testing and record failures Canadian NHP exporters must fix before an inspection.
#Natural Health Products
By Mussarat Fatima
September 28, 2026 · Pharmaceuticals
Health Canada's September 2026 safety review found a possible increased risk of weight loss in children under 6 from ADHD stimulants, and will update the product monographs for the whole class. Here is what market authorization holders must do.
#Pediatric Drugs
By Mussarat Fatima
September 28, 2026 · Food and Beverages
One contaminated imported ingredient ended up in nearly 300 recalled products. Here is what the pistachio Salmonella outbreak teaches Canadian food businesses about SFCR supplier qualification and lot traceability.
#Salmonella
By Mussarat Fatima
September 26, 2026 · Medical Device
FDA has classified whole room microbial reduction devices and a cardiac ablation esophageal protection device into Class II with special controls. Here is what the September 2026 Federal Register orders change, and how manufacturers can turn a new Class II regulation into a faster 510(k) pathway.
#Class II Reclassification
By Mussarat Fatima
September 26, 2026 · Medical Device
FDA has added ISO 10993-1:2025 to its recognized consensus standards with partial recognition. Here is what changed, what the agency will not accept, and how device makers should re-map their biocompatibility files before the 1 July 2029 transition deadline.
#ISO 10993-1
By Mussarat Fatima
September 25, 2026 · Food and Beverages
A frozen-dessert recall over stones in cashew inclusions is a reminder that physical hazards are as real as pathogens. How to identify and control foreign material in ready-to-eat foods under the Safe Food for Canadians Regulations and HACCP.
#Safe Food for Canadians
By Mussarat Fatima
September 25, 2026 · Pharmaceuticals
FDA's September 2026 warning letter to Empower Pharmacy shows where enforcement is focused: GLP-1 compounding scope now that shortages are over, aseptic process control, and data integrity. A practical breakdown for sterile compounders and manufacturers.
#FDA
By Mussarat Fatima
September 24, 2026 · Medical Device
On September 2, 2026, Health Canada replaced the exceptional-importation device forms FRM-0577 and FRM-0578 with web forms, cut the notification window from five business days to three, and added a manufacturer QMS certification requirement. Here is what device importers must change today.
#Medical Devices
By Mussarat Fatima
September 24, 2026 · Regulatory Affairs
The FDA's new Expedited IND Pilot uses rolling review to shorten the path to first-in-human trials. Applications close October 30, 2026, and the first cohort is small. Here is how Canadian sponsors can decide whether to apply and how to prepare a submission in time.
#FDA
By Mussarat Fatima
September 23, 2026 · Regulatory Affairs
British Columbia now captures vapes as battery-containing products under its Recycling Regulation. Producers must submit an Extended Producer Responsibility plan by 15 December 2026. Here is what to file and why federal licensing does not cover it.
#Extended Producer Responsibility
By Mussarat Fatima
September 23, 2026 · Cosmetics and Personal Care
Health Canada has proposed new prohibited and restricted entries for the Cosmetic Ingredient Hotlist. Here is what is changing, which ingredients are affected, and how cosmetics brands and importers should prepare.
#Cosmetic Ingredient Hotlist
By Mussarat Fatima
September 22, 2026 · Pharmaceuticals
Health Canada's 14 September 2026 notice proposes a 180-day review for certain pediatric drug submissions tied to the Ministerial Reliance Order. Here is who qualifies, what the 180 days do and do not promise, and what your dossier must prove on day one.
#Health Canada
By Mussarat Fatima
September 22, 2026 · Medical Device
Health Canada's 16 July 2026 notice to industry changed the ground rules for Class III and IV medical device licence applications. Here is what your dossier must contain, what triggers an Additional Information Request, and how to file for a first-pass decision.
#Medical Devices
By Mussarat Fatima
September 21, 2026 · Medical Device
FDA has published draft guidance introducing the eSTAR electronic submission template for Premarket Approval Applications. Here is what the PMA eSTAR is, why it turns content gaps into upfront blockers, and how Canadian Class III device makers should prepare before the 17 November 2026 comment deadline.
#Medical Devices
By Mussarat Fatima
September 21, 2026 · Good Production Practices
Health Canada bars extraction, packaging and labelling until a cannabis lot has met the mandatory pesticide testing requirements. Here is what a QAP may still do while results are pending, and how to write a release SOP that survives inspection.
#Pesticide Testing
By Mussarat Fatima
September 20, 2026 · Pharmaceuticals
A 14 September 2026 Health Canada notice launches a pilot to request new and updated data during Access Consortium work-sharing reviews, often avoiding a notice of deficiency or non-compliance. The flexibility is bounded, and submissions must still be complete at filing. Here is what NASWSI and GMWSI sponsors should do.
#Health Canada
By Mussarat Fatima
September 20, 2026 · Compliance
Health Canada's compliance and enforcement policy POL-0001 version 10 is in force as of 15 September 2026. It names seven product classes, sets out three categories of action and a graduated enforcement ladder, and keeps the section 31.2 penalty ceiling of $5 million. Here is what to re-verify.
#Health Canada
By Mussarat Fatima
September 19, 2026 · Pharmaceuticals
On 14 September 2026, Health Canada issued an interim policy advancing three elements of clinical trial modernization ahead of the proposed Clinical Trials Regulations. Here is what changes for REBs, investigators and consent, and how it collides with the 1 October ICH E6(R3) deadline.
#Clinical Trials
By Mussarat Fatima
September 19, 2026 · Natural Health Products
Health Canada recall RA-82618 pulled three Organika gummy products because they were made at a foreign site not listed on the company's site licence. Here is what NHP importers must verify, and how a site licence amendment fixes the gap.
#Natural Health Products
By Mussarat Fatima
September 18, 2026 · Medical Device
FDA small business status does not roll over. It expires 30 September 2026, and re-qualifying as a Canadian firm means filing a CRA National Taxing Authority Certification, not a US tax return. Missing it costs USD 21,490 on a single 510(k).
#FDA
By Mussarat Fatima
September 18, 2026 · Quality Assurance
Health Canada published new guidance on validating analytical methods in cannabis testing on 15 September 2026. It reaches cultivators and processors, not only labs. Here is the QAP checklist for the criteria you must verify in validation packages and certificates of analysis.
#Cannabis
By Mussarat Fatima
September 17, 2026 · GMP
The EMA has begun revising EU GMP Part IV, the standalone GMP guideline for Advanced Therapy Medicinal Products, to align it with the revised Annex 1 and its contamination control strategy thinking. This guide explains what Part IV is, what the revision will pull in, the concept paper timetable, and what cell and gene therapy manufacturers, including Canadian sites, should do now to prepare.
#ATMP
By Mussarat Fatima
September 17, 2026 · Food and Beverages
On 15 September 2026 the CFIA recalled Alasko frozen raspberries for possible norovirus contamination. Most Preventive Control Plans identify bacteria, chemicals, allergens and physical hazards, then stop. Freezing does not inactivate norovirus, and there is no kill step in a frozen fruit process. This guide explains why viruses are a hazard under the Safe Food for Canadians Regulations and how to close the gap in your PCP.
#Preventive Control Plan
By Mussarat Fatima
September 16, 2026
Health Canada is rewriting cannabis research rules, with a Canada Gazette comment window expected in fall 2026. What section 28.01 already changed, who it affects, and how to prepare.
#Cannabis
By Mussarat Fatima
September 15, 2026 · Medical Device
The FDA states on the record that a firmware correction was not reported to customers, and up to 196 units were never fixed. A teardown of 21 CFR 806 and the Canadian parallel duty.
#Medical Devices
By Mussarat Fatima
September 15, 2026 · Regulatory Affairs
Six regulatory instruments land on 1 October 2026, with five more deadlines in the run-up. This countdown maps each change to a concrete action for Canadian licence holders.
#Health Canada
By Mussarat Fatima
September 11, 2026 · Pharmaceuticals
EMA gave GVP Module III Revision 2 a legal effective date of 10 September 2026, one day after publication. It rewrites how EU pharmacovigilance inspections handle subcontracting and strengthens the risk-based inspection cycle. Here is what changed, and why it reaches Canadian companies with EU marketing authorisations.
#Pharmacovigilance
By Mussarat Fatima
September 11, 2026 · Pharmaceuticals
On 1 October 2026, Health Canada's updated summary reports guidance replaces the 2018 version. Annual summary reports move to on-request submission, and significant changes are notified on a new form. The duty to prepare a report every year does not change. Here is what DIN and NPN holders must update before the first written request arrives.
#Health Canada
By Mussarat Fatima
September 10, 2026 · GMP
Between 10 September and 1 October 2026, three separate EU and PIC/S GMP changes take effect: the EMA inspection-coordination procedure v3, revised Annex 19, and PIC/S PI 006-4 on qualification and validation. Here is what each changes and what Canadian exporters and validation teams should do.
#EU-GMP
By Mussarat Fatima
September 10, 2026 · Regulations
SOR/2025-244 quietly rewrites dozens of provisions of the Cannabis Regulations, and it comes into force on 1 October 2026 with no transitional period. This guide walks Canadian licence holders, dealers and pharmacists through what changes and what to do before the deadline.
#Cannabis
By Mussarat Fatima
September 9, 2026 · License
Cannabis annual regulatory fee invoices and the medical-sale exemption declaration are both due by 30 September 2026. If you miss the declaration deadline, Health Canada must refuse it. This is a deadline explainer with the verified fee figures, the exemption rules and a filing checklist.
#Cannabis Licensing
By Mussarat Fatima
September 9, 2026 · Pharmaceuticals
On 1 October 2026, Health Canada shrinks the list of specified foreign regulatory authorities under section C.01.050 from 41 to 22. The 72 hour reporting clock is unchanged, but every pharmacovigilance procedure that names the old list is now out of date. Here is what changed and the practical steps to take.
#Pharmacovigilance
By MF License and Regulatory Consultants-MFLRC
September 8, 2026 · Regulatory Affairs
FDA has opened a public docket on botanical drug products, with comments due 3 November 2026. Here is what the RFI asks and what it means for Canadian NHP and cannabis companies eyeing a US drug pathway.
#Botanical Drugs
By Mussarat Fatima
September 8, 2026 · Pharmaceuticals
Effective 1 September 2026, Health Canada limits generic drug sponsors to one 90-day extension per NOD or NON, for a 180-day total. Here is what changed and how to respond in time.
#Generic Drugs
By Mussarat Fatima
September 7, 2026 · Food and Beverages
Selling fish into the United States means meeting US seafood HACCP under 21 CFR Part 123, not just the SFCR. Here is how the two frameworks compare, why fish is exempt from FSVP, and the records your American importer will demand.
#Seafood HACCP
By Mussarat Fatima
September 7, 2026 · Food and Beverages
Cold-smoked salmon has no kill step, a moist matrix and a long refrigerated shelf life, which is exactly what Listeria needs. Here is how to classify a growth-support food and build an environmental monitoring programme that finds Listeria before CFIA or FDA does.
#Listeria
By Mussarat Fatima
September 6, 2026 · Regulatory Affairs
Vanessa's Law gave Health Canada the power to order recalls, require label changes, compel testing, and fine up to $5 million a day. Here is what the Act requires, how mandatory hospital reporting works, and what it means for your compliance programme.
#Vanessa's Law
By Mussarat Fatima
September 6, 2026 · Pharmaceuticals
FDA's 2026 warning letters keep citing failed media fills, with product released anyway. Here is what aseptic process simulation requires, the acceptance criteria that govern it, and how to respond when a run fails.
#Aseptic Processing
By MF License and Regulatory Consultants-MFLRC
September 5, 2026 · Food and Beverages
A cross-Canada Salmonella outbreak tied to imported pistachios has reached 200 confirmed cases. It is a textbook low-moisture food failure. Here is why Salmonella survives in dry foods, and the preventive control plan gaps that let it through.
#Salmonella
By Mussarat Fatima
September 5, 2026 · Pharmaceuticals
On 24 June 2026 the FDA reissued its draft guidance on substantial evidence of effectiveness, clarifying when a single adequate and well-controlled trial supported by confirmatory evidence can support approval. Here is what changes, and how Canadian sponsors should map it onto Health Canada pathways.
#FDA
By Mussarat Fatima
September 4, 2026 · Pharmaceuticals
The Notice of Compliance with Conditions lets Health Canada approve promising drugs early, in exchange for confirmatory studies. Here is how the pathway works, what conditions attach, and how agile licensing changes it in 2027.
#NOC/c
By Mussarat Fatima
September 4, 2026 · Food and Beverages
Most food businesses assume the CFIA runs every recall. It does not. Here is how federal and provincial jurisdiction is decided, what the SFCR requires of you, and how to prepare for either outcome.
#CFIA
By Mussarat Fatima
September 3, 2026 · Pharmaceuticals
Glass, fibre and cellulose recalls hit injectables in 2026 just as USP 788 was retitled. Here is what USP 788, 790 and 1790 require and how to build inspection and CAPA controls that survive an audit.
#Sterile Injectables
By Mussarat Fatima
September 2, 2026 · Regulatory Affairs
The MHRA has confirmed microbiome medicines sit inside the existing UK medicines framework. Here is what that means, and how Canada, the EU and the US classify the same products.
#MHRA
By Mussarat Fatima
September 2, 2026 · Quality Assurance
A cracked cartridge recall shows why container closure integrity is a separate quality attribute from the drug. Here is what Canadian injectable makers should test, validate and audit.
#Pharmaceuticals
By Mussarat Fatima
September 1, 2026 · Pharmaceuticals
A trial that supported Tavneos in 2022 helped unwind its approval in 2026. Here is how a data handling problem became an approval problem, and what sponsors and CROs must do to make their own trial data survive scrutiny.
#Pharmaceuticals
By Mussarat Fatima
September 1, 2026 · Natural Health Products
Health Canada completed a Summary Safety Review of oral ashwagandha and found a possible link to liver injury that cannot be ruled out. Here is what the finding means and the exact steps NHP licence holders should take now.
#Natural Health Products
By Mussarat Fatima
August 31, 2026 · Compliance
Health Canada grades health product recalls Type I, II and III. CFIA grades food recalls Class I, II and III. Here is what each level signals, how it is assigned, and the timelines you must meet.
#Recall Classification
By Mussarat Fatima
August 30, 2026 · Natural Health Products
A 25 August 2026 Type I recall pulled two herbal products spiked with undeclared sildenafil. For NHP licence holders, it is a map of the exact quality controls, identity testing, adulterant screening, finished product specs, and supplier qualification, that keep adulteration out of your supply chain.
#Natural Health Products
By Mussarat Fatima
August 29, 2026 · Pharmaceuticals
FDA's new draft guidance, GFI #256B, would extend enforcement discretion to federally-registered facilities that compound animal drugs from bulk substances under CGMP. Here is what it changes, and why Canadian exporters and contract manufacturers should read it.
#FDA
By Mussarat Fatima
August 29, 2026 · Pharmaceuticals
In one month, Health Canada published three Type II recalls of generic semaglutide injection from two manufacturers. Each one exposes a different quality failure that every generic injectable and pen programme should design out.
#Semaglutide
By Mussarat Fatima
August 28, 2026 · Food and Beverages
A 2026 Cyclospora outbreak tied to imported lettuce has grown past 11,000 illnesses, and the wider US season now exceeds 17,000 cases across multiple clusters. Here is why most preventive control plans miss parasitic hazards, and what Canadian importers must fix.
#Preventive Control Plan
By Mussarat Fatima
August 28, 2026 · Food and Beverages
A cluster of Quebec botulism warnings on chiktay and Creole marinades in sealed jars traces to one root cause: low-acid food sold without a validated process or a Keep Refrigerated label. Here is what a defensible preventive control plan must prove.
#Preventive Control Plan
By Mussarat Fatima
August 27, 2026 · Food and Beverages
The CFIA comment period on the SFCR unmet slaughter capacity rule closed on 26 August 2026. Here is what the four-year interprovincial red meat exemption would cover, who qualifies, and how provincial plants should prepare for the Part II final regulation.
#CFIA
By Mussarat Fatima
August 27, 2026 · Natural Health Products
Probiotics are Natural Health Products in Canada, and the rules follow from one fact: the ingredient is alive. A practical guide to strain identity, viable CFU counts, stability dating, claims, and where postbiotics differ.
#Probiotics
By Mussarat Fatima
August 26, 2026 · Pharmaceuticals
Health Canada can list a foreign-authorized drug for exceptional importation, but only a DEL holder can bring it in. Here are the licensing, GMP and quality duties the importer inherits.
#Drug Establishment Licence
By Mussarat Fatima
August 26, 2026 · Pharmaceuticals
On 24 August 2026 Health Canada let South Korean-authorized BONKY calcitriol fill a Canadian shortage. Here is how the exceptional importation pathway and designated drugs actually work.
#Exceptional Importation
By Mussarat Fatima
August 25, 2026 · Medical Device
FDA refreshed its recognized consensus standards on 24 August 2026. Here is how a Declaration of Conformity works inside an Abbreviated 510(k), what Recognition List 066 changed, and how to avoid the additional information request that costs you weeks.
#FDA
By Mussarat Fatima
August 24, 2026 · Pharmaceuticals
Clean-in-place and steam-in-place are not just engineering conveniences. They are validated GMP processes governed by cleaning and sterilization guidelines from Health Canada, the EU and the FDA. Here is what CIP and SIP must demonstrate, and the guidelines that require it.
#Cleaning Validation
By Mussarat Fatima
August 24, 2026 · Good Production Practices
Health Canada has clarified that the preventive control plan for cannabis products made with intoxicating cannabinoids other than delta-9-THC must identify and control chemical contamination from cannabinoid synthesis and its by-products. Here is what delta-8, THC-O and CBN producers must build into their PCP.
#Cannabis
By Mussarat Fatima
August 24, 2026 · Pharmaceuticals
The EMA GMDP Inspectors Working Group has published a three-year work plan that will revise most of the EU GMP Guide by 2028, including a first-ever Annex 22 on artificial intelligence. Here is the full dated roadmap and what pharmaceutical manufacturers and EU-GMP cannabis exporters should do now.
#EU-GMP
By Mussarat Fatima
August 23, 2026 · Food and Beverages
FSVP is the US importer's legal duty, but the verification burden flows down to you. Here is what a US importer will demand of a Canadian food exporter and how to be ready before the request arrives.
#FSVP
By Mussarat Fatima
August 22, 2026 · Medical Device
The UK's draft Medical Devices (Amendment) Regulations 2026 name Canada a comparable regulator and propose an international reliance route to the Great Britain market. Here is what Canadian device makers should do to prepare.
#Medical Devices
By Mussarat Fatima
August 21, 2026 · Pharmaceuticals
The EMA eAF changes twice in 2026: the interactive-PDF v1.28.1.0 becomes mandatory for human variations on 24 August, and the PLM web-based eAF for centrally authorised products on 1 September. Here is what regulatory teams must do before each date.
#Pharmaceuticals
By Mussarat Fatima
August 21, 2026 · Natural Health Products
Your Health Canada NPN does not travel across the border, and FDA cGMP enforcement is rising in 2026. This guide shows Canadian NHP companies what 21 CFR Part 111 demands, what recent warning letters reveal, and how to get export ready, from facility registration and a US Agent to identity testing, finished batch specifications, NDI notifications and the importer's FSVP duties.
#Natural Health Products
By Mussarat Fatima
August 21, 2026 · Food and Beverages
A 2026 CFIA cheese recall for generic E. coli made nobody sick, yet it is a serious warning. Learn what a non-pathogenic recall says about your SFCR preventive control plan, and the root causes and CAPA that actually close the gap.
#CFIA
By Mussarat Fatima
August 20, 2026 · Food and Beverages
A single jalapeno grower in Sinaloa set off Salmonella recalls across many brands and into Canada. Here is what the outbreak reveals about single source risk, and what the Safe Food for Canadians Regulations demand for supplier control and traceability.
#Safe Food for Canadians
By Mussarat Fatima
August 20, 2026 · Food and Beverages
FDA's August 2026 public meeting on Listeria prevention is the first in a series and signals tougher, more risk based expectations. Here is what Canadian ready to eat and retail food businesses should audit now under the Safe Food for Canadians Regulations.
#Environmental Monitoring
By Mussarat Fatima
August 19, 2026 · Food and Beverages
A single Quebec charcuterie plant's Listeria recall spread across four brands and ended in a suspended Safe Food for Canadians licence. Here is what it teaches brand owners about co-manufacturer oversight, environmental monitoring and corrective action.
#CFIA
By Mussarat Fatima
August 19, 2026 · Pharmaceuticals
FDA has revised its guidance on choosing between an ANDA and a 505(b)(2) application. Here is how the decision works, why the duplicate rule can remove your choice, and what Canadian sponsors should check before they file.
#FDA
By Mussarat Fatima
August 18, 2026 · Food and Beverages
Sections 86 and 87 of the SFCR exempt some small food businesses under $100,000 in sales from a written preventive control plan. See who qualifies, which foods are excluded, and why the controls still apply.
#Preventive Control Plan
By Mussarat Fatima
August 18, 2026 · Medical Device
FDA has proposed classifying seven device accessories as Class I and 510(k)-exempt. See the list, the design-control test that decides eligibility, the Canadian angle, and the 16 October 2026 comment deadline.
#Medical Devices
By Mussarat Fatima
August 17, 2026 · Food and Beverages
On 13 August 2026, Health Canada modified the List of Permitted Supplemental Ingredients to allow up to 30% juice in certain caffeinated supplemented beverages. The change is permissive and effective immediately, but it carries a Supplemented Food Facts obligation many manufacturers will miss.
#Supplemented Foods
By Mussarat Fatima
August 17, 2026 · Pharmaceuticals
Health Canada's Type I Teva-Pregabalin recall found one prescription drug inside another. We break down what it means for cleaning validation, changeover control and cross-contamination prevention in Canadian manufacturing, with a practical checklist.
#Cleaning Validation
By Mussarat Fatima
August 16, 2026 · Regulatory Affairs
Regulation (EU) 2025/40, the PPWR, applies from 12 August 2026 and replaces Directive 94/62/EC. Here is what the new packaging rules mean for cosmetics, food and pharma exporters.
#EU Packaging Regulation
By Mussarat Fatima
August 15, 2026 · Pharmaceuticals
FDA has proposed the PDUFA VIII commitment recommendations for fiscal years 2028 to 2032. Two changes hit non-US sponsors directly, and a new CMC facility lifecycle program puts pre-approval inspection readiness at the centre of drug approval. Here is what changed and what to say before the 16 October 2026 comment deadline.
#PDUFA
By Mussarat Fatima
August 14, 2026 · Pharmaceuticals
FDA finalized its formal meetings guidance on 13 August 2026, adding Type D scenarios, clarifying INTERACT, and describing the meeting formats it may grant. Here is a plain-language guide to the meeting types, timelines, and a complete meeting request.
#FDA
By Mussarat Fatima
August 14, 2026 · Natural Health Products
As of 2 June 2026, melatonin sold for sleep-related use in anyone under 18 is a prescription drug in Canada, with no transition period. Here is what the new Prescription Drug List qualifier really says and what your NHP portfolio must check now.
#Natural Health Products
By Mussarat Fatima
August 13, 2026 · Food and Beverages
On 11 August 2026 FDA proposed a mandatory GRAS notification programme that would end the self-affirmed GRAS pathway. Here is what Canadian food, supplemented food and NHP ingredient suppliers need to know, and why a US GRAS conclusion still means nothing in Canada.
#GRAS
By Mussarat Fatima
August 12, 2026 · GMP
Inadequate personnel training under 21 CFR 211.25(a) is one of the most persistent findings in FDA Form 483 observations and warning letters. Here is exactly what the regulation requires and how to build a training system that survives an inspection.
#FDA
By Mussarat Fatima
August 12, 2026 · Pharmaceuticals
FDA finalised Psychedelic Drugs: Considerations for Clinical Investigations on 14 July 2026 and opened a Part 15 public hearing with a 21 August registration deadline. Here is what changed, what did not, and what sponsors should do next.
#FDA
By Mussarat Fatima
August 11, 2026 · Pharmaceuticals
EMA has published its first Article 117-compliant Shortage Prevention Plan guidance. Here is who needs an SPP, the minimum data set from Part V of Annex IV, the two-day request rule, and how to build a plan that is ready before EMA asks.
#Drug Shortages
By Mussarat Fatima
August 11, 2026 · Medical Device
A plain-language guide to medical device recall reporting in Canada. What counts as a recall under SOR/98-282, the 24-hour notification, the FRM-0360 forms, reporting timelines, and how to build a recall procedure that survives a Health Canada review.
#Medical Devices
By Mussarat Fatima
August 10, 2026 · Pharmaceuticals
FDA can now build a full warning letter without ever visiting your facility, using a records request under section 704(a)(4) of the FD&C Act. In 2026 these letters hit OTC drug makers across three continents. Here is how the tool works and how to be ready before one arrives.
#FDA
By Mussarat Fatima
August 10, 2026 · Pharmaceuticals
The European Commission has revised EU GMP Annex 19 for the first time since 2006. Applicable 24 September 2026, it adds new parallel-trade sampling rules and a controlled digital retention sample route. Here is what importers, QPs and parallel distributors must change now.
#EU-GMP
By Mussarat Fatima
August 9, 2026 · Medical Device
Health Canada is changing how it maintains the List of Recognized Standards for medical devices, moving to continuous feedback. Recognized standards drive your conformity evidence, so here is how to build standards surveillance into your quality system.
#Medical Devices
By Mussarat Fatima
August 9, 2026 · Food and Beverages
A Class 1 recall of a plant-based snack for undeclared milk shows why a vegan or dairy-free claim is a control point in your preventive control plan, not marketing copy. Here is how to build the control.
#Allergen Control
By Mussarat Fatima
August 8, 2026 · Natural Health Products
Two Health Canada NHP label recalls in eight days. Here is exactly what the Natural Health Products Regulations require for allergen declaration, section by section, and where licence holders keep getting caught.
#Natural Health Products
By Mussarat Fatima
August 7, 2026 · Food and Beverages
Two Listeria recalls in 48 hours, one detected by CFIA rather than the operator. When the regulator finds a positive your own program missed, the problem is the program. Here is how to build environmental monitoring that finds it first.
#Preventive Control Plan
By Mussarat Fatima
August 7, 2026 · Pharmaceuticals
Health Canada's July 2026 guidance suite formalizes how sponsors self-classify non-prescription drugs as Division 1 or Division 8. Getting it wrong means the wrong application, the wrong fee, and a refiling. Here is the decision framework, decoded.
#Non-prescription Drugs
By Mussarat Fatima
August 6, 2026 · Food and Beverages
Hershey's Kisses were recalled nationally in August 2026 for undeclared almond after roughly twelve weeks on the market. The gap points to an SFCR allergen control plan that manages cross-contact, changeover and finished-product verification, not just the label. Here is what CFIA expects.
#Allergen Control
By Mussarat Fatima
August 6, 2026 · Compliance
Every disinfectant DIN and every registered sanitizer moving to Canada's Biocides Regulations needs new label text, not just a transition application. Here is what has to change on the principal display panel, the five settings for use, and the claims that will get a label rejected.
#Biocides
By Mussarat Fatima
August 5, 2026 · Pharmaceuticals
On 29 July 2026 Health Canada launched a public clinical trials search portal and finalised its guidance on registering trials and disclosing results. Here is what the guidance expects of sponsors, which trials are in scope, and how to build a compliant registration and disclosure procedure.
#Clinical Trials
By Mussarat Fatima
August 5, 2026 · Compliance
The Biocides Regulations put a recall obligation on any person that has sold a biocide in Canada, not just manufacturers. Here is what sections 48 to 50 require, the 24-hour and 72-hour clocks, the records rule, and how to build a recall system that holds up.
#Biocides
By Mussarat Fatima
August 4, 2026 · Regulatory Affairs
Canada's free, no-efficacy-data biocides transition application closes 31 May 2029. Here is what disinfectant and sanitizer holders must file, which pathway applies, and the deadline that really matters.
#Biocides
By Mussarat Fatima
August 4, 2026 · Pharmaceuticals
A Canadian kit recall shipped two cartons of one drug and none of the other. Here is what line clearance, segregation and reconciliation should have caught, and how to build packaging controls that pass inspection.
#Packaging Validation
By Mussarat Fatima
August 3, 2026 · Food and Beverages
A cluster of Canadian shrimp recalls in 2026 shared one cause, the banned nitrofuran marker AOZ. Most importer preventive control plans are built around pathogens and allergens and treat chemical residues as a supplier attestation. Here is what the SFCR actually requires, and how to close the gap.
#Preventive Control Plan
By Mussarat Fatima
August 3, 2026 · Cannabis regulations, label, Quality assurance,
Health Canada inspectors found undeclared milk and hazelnut in vegan edible cannabis, plus THC and CBD results that did not match the label, after fourteen months of sales. Here is what recall RA-82393 means for your allergen control, potency accuracy and QA programme.
#Cannabis
By Mussarat Fatima
August 2, 2026 · Pharmaceuticals
Health Canada wants feedback on a time-limited pilot that would move certain generic drug submissions involving domestic manufacturing up the review queue. Here is what is confirmed, what is still open, and how to prepare a response before the 12 September 2026 deadline.
#Generic Drugs
By Mussarat Fatima
August 2, 2026 · Pharmaceuticals
The WHO Ebola PHEIC has disinfectant makers asking what they can claim. Under Canada's Biocides Regulations, an indirect virucidal claim needs a WHO-declared pandemic, and a PHEIC is not one. Here is what you can legally say, plus the 2029 transition deadline every DIN holder must plan for.
#Biocides
By Mussarat Fatima
August 1, 2026 · GMP
A validation master plan is the document that ties every qualification and validation activity on a GMP site into one governed, risk-based strategy. This guide explains what a VMP must contain under EU GMP Annex 15, Health Canada GUI-0029, the FDA lifecycle approach, and the new PIC/S PI 006-4 in force from 1 October 2026, and how to build one that holds up in an inspection.
#Process Validation
By Mussarat Fatima
August 1, 2026 · Pharmaceuticals
FDA revised 17 peptide product-specific guidances and withdrew its 2021 synthetic-peptide guidance. Here is what ANDA sponsors must change before the 28 September 2026 comment deadline.
#Peptides
By Mussarat Fatima
July 31, 2026 · Natural Health Products
Health Canada has released a draft revised Quality of Natural Health Products Guide, the first update since 2015. It tightens purity, elemental impurity and stability expectations and confirms what a finished product specification must show under paragraph 44(2)(a). Here is what changed and what NHP licence holders should do before the consultation closes on 20 September 2026.
#Natural Health Products
By Mussarat Fatima
July 30, 2026
Health Canada's revised Natural Health Product Raw Material Policy sets out how to tell a raw material from a finished NHP, and the answer decides whether you need a site licence and product licence. Here is the test, the licensing outcomes, and the traps for importers.
#Natural Health Products
By Mussarat Fatima
July 30, 2026
NNHPD Bulletin No. 11 removed the expectation to file a finished product specification with Class II and III NHP applications. The legal duty to hold one has not changed. Here is what moved, what did not, and how to keep your FPS inspection-ready.
#Natural Health Products
By Mussarat Fatima
July 29, 2026 · Natural Health Products
Section 52 of the Natural Health Products Regulations requires manufacturers and importers to establish a defensible shelf life. Under GUI-0158 Version 4.0 that means a completed study, a written protocol and a QAP approved report for every product you market in Canada.
#Natural Health Products
By Mussarat Fatima
July 28, 2026 · Pharmaceuticals
For years, contamination control strategy was framed as a sterile-manufacturing concern. EMA's July 2026 Q&A makes clear that non-sterile medicine makers must apply the same disciplined thinking. This guide breaks down the organisational and technical measures EMA expects, how they connect to Annex 1 and quality risk management, and the practical steps to close the gap before an inspection does.
#EU-GMP
By Mussarat Fatima
July 27, 2026 · Regulations
Health Canada has opened a central guidance repository under its cannabis red tape reduction plan. Import permits now run up to 12 months, odour plans are no longer assessed at application, and hemp and intoxicating-cannabinoid guidance has been clarified. Here is what changed and what licence holders should update.
#Cannabis
By Mussarat Fatima
July 26, 2026 · Quality Assurance
How to build a supplier qualification programme that holds up under Health Canada, FDA and EU inspection, using risk tiering, enforceable quality agreements and audit depth matched to tier.
#Quality Management System
By Mussarat Fatima
July 26, 2026 · Medical Device
FDA's final human factors guidance takes effect August 1, 2026, and the updated eSTAR templates now ask every device maker to declare a human factors submission category. Here is what the three categories mean, how the new Decision Point D works, and what to do before you file.
#Human Factors
By Mussarat Fatima
July 26, 2026 · Pharmaceuticals
Peptides like BPC-157 are marketed as wellness products, but Health Canada regulates most of them as unapproved prescription drugs. Here is how Canada classifies peptides, why selling them is illegal, and what a compliant pathway actually requires.
#Peptides
By Mussarat Fatima
July 25, 2026 · Regulatory Affairs
The revised EU variations framework applies from 15 January 2026. What changes for marketing authorisation holders, including new classification codes, super-grouping, work-sharing and Type IA annual updates.
#Pharmaceuticals
By Mussarat Fatima
July 25, 2026 · Quality Assurance
Cosmetic GMP and ISO 22716 explained across Canada, the EU and the US, with a compliance checklist, common mistakes and a real FDA inspection lesson for brands and contract manufacturers.
#ISO 22716
By Mussarat Fatima
July 24, 2026 · Food and Beverages
A recall is not the moment to discover your traceability has gaps. This practical guide shows Canadian food, cannabis and health-product businesses how to run an SFCR mock recall, measure effectiveness, and close the gaps before the CFIA calls.
#Recall Readiness
By Mussarat Fatima
July 23, 2026 · Quality Assurance
SOPs fail inspections for three reasons: complicated language, no standardization, and training that lags document revisions. Compare the weak clause and the defensible clause for the 10 most-inspected SOPs, then score your own set.
#SOPs
By Mussarat Fatima
July 20, 2026 · Pharmaceuticals
The revised EMA Guideline on the chemistry of active substances applies from 1 September 2026. Learn how to justify your API starting materials, handle recovery and reprocessing, and connect nitrosamine risk before the deadline.
By Mussarat Fatima
July 17, 2026 · Natural Health Products
Health Canada's red-tape review will simplify NHP licensing and post-market obligations. The first comment period closed on 14 July 2026, with a Ministerial Order targeted for fall 2026. Here is the updated timeline and how NHP companies should prepare.
#Natural Health Products
By Mussarat Fatima
July 16, 2026 · Compliance
Health Canada is preparing Cannabis Tracking System Order amendments to cut duplicative monthly reporting, with Canada Gazette, Part I expected in fall 2026. Nothing has changed yet: reports are still due by the 15th. Here is what the Notice of Intent signals, which CTSO fields are most exposed, and the eight-step field mapping LPs should complete before pre-publication.
#Cannabis
By Mussarat Fatima
July 16, 2026 · Regulatory Affairs
On 16 July 2026, Regulations (EU) 2025/2091 and 2025/2154 make veterinary GMP directly binding EU law, separate from EudraLex Volume 4. Here is what changes, who is affected including Canadian exporters, and how to remap your SOPs and supplier files.
#EU-GMP
By Mussarat Fatima
July 15, 2026 · GMP
Health Canada expects a state of readiness for an inspection at any time. Score your site out of 25 against Part C, Division 2, GUI-0001 and GUI-0023, then read your band: audit-ready, gaps to close, material exposure, or call a consultant.
#Inspection Readiness
By Mussarat Fatima
July 14, 2026 · Compliance
Health Canada has refused or revoked over 5,600 personal and designated medical cannabis registrations since 2018. Here is what the crackdown means for compliance.
#Cannabis
By Mussarat Fatima
July 12, 2026 · Compliance
Cannabis retail is regulated province by province in Canada. This overview maps the authority, wholesaler and retail model for all 13 provinces and territories.
#Cannabis
By Mussarat Fatima
July 10, 2026 · Quality Assurance
Audit trail review, not audit trail generation, is the 2026 data integrity battleground. Learn the FDA and Health Canada rules, the ALCOA+ standard, and a five-step programme to close the gap on shared logins and unvalidated systems before inspectors do.
#Data Integrity
By Mussarat Fatima
July 10, 2026 · GMP
Germany's Hesse authority now treats cannabis drying as a GMP step, challenging the GACP-at-source, GMP-in-Europe model that carries most of Canada's flower into its largest market. Here is what changed and the practical path to stay compliant.
#EU-GMP
By Mussarat Fatima
July 9, 2026 · Quality Assurance
Most failed CAPAs are not action failures, they are diagnosis failures. Here is why CAPAs keep reopening and how to build root cause investigations that survive a 2026 inspection across pharma, NHP, cannabis, food, and medical devices.
#FDA
By Mussarat Fatima
July 8, 2026 · Regulatory Affairs
Selling vitamins, minerals or traditional remedies for pets or livestock in Canada? Learn the 30-day VHP notification rule, the Permitted Substances List (List C) and your Part 3 GMP obligations.
#Veterinary Health Products
By Mussarat Fatima
July 8, 2026 · Natural Health Products
GUI-0158 is in force and the FSRN process is discontinued. Foreign site GMP evidence must now be filed inside each importer's NHP site licence application. Here is what NHP importers and distributors must do now.
#Natural Health Products
By Mussarat Fatima
July 5, 2026 · Compliance
A dual look at a common question: the pharmacology of cannabis and antibiotic drug interactions, and the strict Cannabis Act promotion rules that govern what licensed producers and retailers are allowed to say about it.
#Cannabis
By Mussarat Fatima
July 5, 2026 · Compliance
Licence renewals and amendments are where many regulated businesses lose ground: a missed deadline can cancel a licence, and an unreported change can trigger a finding. Here is how experienced regulatory consultants manage both across cannabis, drug, medical device and natural health product licences.
#Compliance
By Mussarat Fatima
July 5, 2026 · Pharmaceuticals
The FDA now holds sponsors accountable when their contract manufacturer, packager, or testing lab fails. Here is what binding quality agreements, supplier audits, and oversight your company needs across pharma, NHP, and devices in 2026.
#FDA
By Mussarat Fatima
July 5, 2026 · Regulatory Affairs
Health Canada's amended drug and device shortage framework (SOR/2026-96) took effect on 17 June 2026. Here is what is law now, what is only proposed, and the ten steps market authorization holders should take.
#Health Canada
By Mussarat Fatima
July 5, 2026 · GMP
On 22 April 2026 the United States moved medical and FDA-approved marijuana to Schedule III. Here is what the two-tier reform means for tax, banking, research and cannabis compliance, and how businesses should prepare.
#Cannabis
By Mussarat Fatima
July 5, 2026 · Compliance
Canada's Natural Health Products Regulations look rigorous on paper. Health Canada's own inspection findings, the six year labelling delay and a half-implemented Vanessa's Law tell a more complicated story. An evidence-based assessment for NHP licence holders.
#Natural Health Products
By Mussarat Fatima
July 3, 2026 · Regulatory Affairs
Health Canada's proposed Foreign Reliance Order (the Ministerial Reliance Order) could speed drug approvals by relying on trusted foreign regulators. Learn the three pathways, who qualifies, and how to prepare a reliance submission.
#Health Canada
By Mussarat Fatima
July 2, 2026 · License
A plain-language 2026 guide to cannabis licensing in Ontario, covering the federal Health Canada production licences, the AGCO retail licences, fees, timelines and the compliance obligations that follow approval.
#Cannabis
By Mussarat Fatima
July 2, 2026 · Regulatory Affairs
Health Canada will formally accept PACMPs for biologic and radiopharmaceutical (BRDD) products after the 90-day ICH Q12 transition ends August 13, 2026. Here is what qualifies, how the two-step PACMP works, and how to prepare.
#Health Canada
By Mussarat Fatima
July 2, 2026 · Regulatory Affairs
A cross-border guide to inspection responses that hold up. What the FDA's March 2026 Form 483 draft guidance requires, how Health Canada's Exit Notice and CAPA process works, and how to keep a finding from escalating into a warning letter or licence action.
#FDA
By Mussarat Fatima
June 30, 2026 · Compliance
In 2025 Health Canada consulted on a pathway for non-prescription CBD health products for people and animals. The proposal has since stalled. Here is what was on the table, where it stands in 2026, and how CBD businesses should plan.
#CBD
By Mussarat Fatima
June 30, 2026 · License
A practical guide to liquor retail licensing across Canada, with Ontario's 2024 to 2026 convenience and grocery rules and a provincial snapshot.
#Liquor Licensing
By Mussarat Fatima
June 30, 2026 · GMP
A clear comparison of Canada's GPP and the EU-GMP pharmaceutical standard, with guidance on choosing the right compliance path for your market.
#EU-GMP
By Mussarat Fatima
June 30, 2026 · Quality Assurance
The FDA's first AI warning letter (Purolea) shows the risk of unreviewed AI records. A practical framework to use AI in GMP documentation with human review, CSV and data integrity, for pharma, NHP, cosmetics and cannabis.
#Artificial Intelligence
By Mussarat Fatima
June 29, 2026 · Pharmaceuticals
The EU-GMP Annex 15 revision will make qualification and validation mandatory for chemical and biological active substance (API) manufacturers, not just finished-product sites. A joint EMA and PIC/S concept paper set the direction, consultation closed in April 2026, and the final text is targeted for publication by December 2026. Here is what the timeline means and how API sites should prepare.
#EU-GMP
By Mussarat Fatima
June 29, 2026 · Pharmaceuticals
The FDA issued 25 warning letters in June 2026 over false or misleading promotion of compounded GLP-1 products. Here is what telehealth, pharmaceutical, and natural health product companies must fix, in the United States and Canada, to stay compliant.
#GLP-1
By Mussarat Fatima
June 27, 2026 · Food and Beverages
On June 25, 2026, the CFIA released its Food Fraud Annual Report 2024 to 2025: 886 authenticity samples tested and more than 150,000 kg of misrepresented food kept off the market. Olive oil had the lowest authenticity compliance and imported honey drove most of the seized volume. Here is what the findings mean for food manufacturers, importers and co-packers, and how to build food fraud controls into your compliance program.
#Food Fraud
By Mussarat Fatima
June 27, 2026 · Pharmaceuticals
Health Canada's revised nitrosamine guidance changes the notification trigger and updates Acceptable Intake limits. Here is what pharmaceutical MAHs must do now to stay compliant.
#Nitrosamine Impurities
By Mussarat Fatima
June 24, 2026 · Food and Beverages
Canada's supplemented foods transition period ended December 31, 2025. CFIA is now verifying Division 29 labels. Here is what a compliant label requires and where to start.
#Supplemented Foods
By Mussarat Fatima
June 23, 2026 · GMP
A practical guide to Health Canada cultivation licence requirements after SOR/2025-43, covering licence classes, the 800 square metre micro limit, security clearances, GPP and the CTLS application path.
#Cannabis
By Mussarat Fatima
June 23, 2026 · Pharmaceuticals
ICH Q1 is being rewritten. One consolidated guideline will replace Q1A-F and Q5C, extend stability testing to biologics and advanced therapies, and tie stability to the product lifecycle. Here is what changes for your stability program.
#Stability Testing
By Mussarat Fatima
June 23, 2026 · GMP
Cannabis licensing in the United States runs state by state while federal law shifts. This guide covers licence types, the April 2026 Schedule III order, new hemp THC limits and how to build a strong application.
#Cannabis
By Mussarat Fatima
June 22, 2026 · Regulatory Affairs
Health Canada has proposed a Ministerial Order to exempt low-risk non-prescription drugs and sunscreens from the new-drug pathway. Here is what it covers, where the compliance risks sit, and how to comment by July 14, 2026.
#Non-prescription Drugs
By Mussarat Fatima
June 22, 2026 · Good Production Practices
Ontario has no such thing as a budtender licence. What the law requires is AGCO Board-approved training before your first shift, plus a Retail Manager Licence once you supervise. Here is the real compliance picture.
#Cannabis Retail
By Mussarat Fatima
June 21, 2026 · Compliance
Texas expanded its Compassionate Use Program in 2025 under HB 46, adding 12 new dispensing organization licences. Here is how the Texas cannabis licence works, who can apply, and what a competitive application requires.
#Cannabis
By Mussarat Fatima
June 20, 2026 · Compliance
A current guide to natural health product compliance in Canada, covering product and site licensing, GMP, Vanessa's Law enforcement, modernized labelling and cost recovery.
#Natural Health Products
By Mussarat Fatima
June 20, 2026 · Cultivation
Integrated Pest Management protects cannabis crops without putting your licence at risk. This 2026 guide covers action thresholds, monitoring, prevention and controls, plus the Health Canada pesticide rules and mandatory testing every licensed producer must meet.
#Cannabis
By Mussarat Fatima
June 20, 2026 · Compliance
A practical, up-to-date guide to labelling compliance in Canada across food, cannabis and natural health products, with 10 ways to prevent costly label errors and recalls.
#Food Labelling
By Mussarat Fatima
June 20, 2026 · Cultivation
Sensory evaluation is a frontline quality control tool for cannabis. Learn how appearance, aroma and texture checks support Health Canada compliance, how they differ from lab testing, and how to build a defensible program.
#Cannabis
By Mussarat Fatima
June 20, 2026 · Medical Device
The FDA's Quality Management System Regulation replaced the QSR on February 2, 2026 and built 21 CFR Part 820 on ISO 13485:2016. Here is what changed, what records FDA can now inspect, and the steps device makers should take to stay compliant.
#FDA
By Mussarat Fatima
June 19, 2026 · Compliance
How experienced cannabis licensing consultants help Canadian licence holders streamline Health Canada compliance, from licensing and SOPs to audits, CTLS reporting and QAP support.
#Cannabis
By Mussarat Fatima
June 19, 2026 · Compliance
A practical, up to date guide to passing a Health Canada cannabis inspection, built around the latest 2025 to 2026 inspection data, the March 2025 rule changes, Good Production Practices, recordkeeping and the right way to handle CAPA.
#Cannabis
By Mussarat Fatima
June 19, 2026 · Regulatory Affairs
Health Canada's MDEL Phase II amendments (SOR/2026-110) take effect December 14, 2026. A practical guide to the foreign distributor exemption, the mandatory supplier list, and the new documented-procedure rules for medical device importers and distributors.
#Health Canada
By Mussarat Fatima
June 19, 2026 · Pharmaceuticals
Data integrity appears in 60-80% of FDA drug GMP warning letters. See the 2026 findings, the ALCOA+ controls that prevent them, and how MFLRC supports gap assessments, audit-trail review, CSV, and CAPA.
#Data Integrity
By Mussarat Fatima
June 18, 2026 · Quality Assurance
A practical, cross-sector guide to writing Health Canada SOPs for cannabis, drugs, NHPs, medical devices and food, with the ALCOA+ standard, common findings and an inspection-ready checklist.
#Health Canada
By Mussarat Fatima
June 18, 2026 · Medical Device
Canada's Phase II MDEL amendments (SOR/2026-110) take effect December 14, 2026. Foreign distributors selling through a licensed Canadian importer no longer need their own MDEL, while supplier lists and documented procedures become mandatory. Here is what importers and distributors must do now.
#Medical Devices
By Mussarat Fatima
June 18, 2026 · Compliance
EU-GMP certification is the key that unlocks Europe for Canadian cannabis producers. This 2026 guide covers the certification process, GACP, GMP and GDP, timelines, a compliance checklist and the most common mistakes to avoid.
#EU-GMP
By Mussarat Fatima
June 17, 2026 · Quality Assurance
Fully documented sterile sites still fail Annex 1 because they cannot show continuous, connected contamination control. Here is how to build an inspection-ready CCS.
#Pharmaceuticals
By Mussarat Fatima
June 16, 2026 · Good Production Practices
Edible cannabis and cannabis extracts look similar but face very different rules. Learn how Health Canada classifies ingestible cannabis products, the 10 mg and 1,000 mg THC limits, the food-format test, and how to stay compliant.
#Cannabis
By Mussarat Fatima
June 16, 2026 · Compliance
Health Canada conducted 889 cannabis inspections in 2024-2025, and the same compliance gaps keep showing up. Learn the top five mistakes licensed producers make, what current inspection data reveals, and the practical fixes that keep you inspection-ready.
#Cannabis
By Mussarat Fatima
June 16, 2026 · Regulatory Affairs
The European Commission, EMA and PIC/S published draft revisions of Annex 11 and Chapter 4 and a brand new Annex 22 on artificial intelligence on 7 July 2025. Finals are expected mid-2026. Here is what changes and how to get ready.
#Compliance
By Mussarat Fatima
June 16, 2026 · Regulatory Affairs
The 2026 federal move placed some marijuana in Schedule III, but that is rescheduling, not legalization. Learn what changed, what did not, and how Canadian licensed producers should prepare.
#Cannabis
By Mussarat Fatima
June 15, 2026 · License
A cannabis business plan in Canada is not just an investor document. It is the blueprint that proves to Health Canada you can operate safely and legally. This 2026 guide covers licence classes, the CTLS, market data, the quality and compliance backbone, financials and the mistakes that sink applications.
#Cannabis
By Mussarat Fatima
June 15, 2026 · Food and Beverages
The CFIA will inspect more than 2,400 licensed-but-uninspected manufactured-food establishments by fall 2026. Here is what the expanded Preventive Control Plan, chemical hazard and food safety culture expectations mean for SFC licence-holders, and how to be inspection-ready.
#CFIA
By Mussarat Fatima
June 15, 2026 · Regulatory Affairs
The FDA's first warning letter to cite AI misuse (Purolea, 21 CFR 211.22(c)). What it means for your Quality Unit and how to govern AI in a GMP environment.
#Pharmaceuticals
By Mussarat Fatima
June 14, 2026 · Regulatory Affairs
Canadian producers supplied 53 percent of Germany medical cannabis imports in Q1 2026. This 2026 roadmap maps the EU-GMP and GACP certification path Canadian LPs need to reach the German pharmacy channel, from gap analysis to overseas inspection.
#Cannabis
By Mussarat Fatima
June 13, 2026 · Natural Health Products
Health Canada's GUI-0158 Version 4.0 came into force March 4, 2026. A compliance checklist, QAP responsibility matrix, and FAQ for Canadian NHP licence holders and importers.
#GUI-0158
By Mussarat Fatima
June 12, 2026 · Regulatory Affairs
ICH E6(R3) Annex 2 was adopted at Step 4 on 3 June 2026, completing the modern GCP framework. Here is how Canadian sponsors and sites can get decentralized trial and real-world data compliance ready before Health Canada's 1 October 2026 deadline.
#Health Canada
By Mussarat Fatima
June 12, 2026 · Regulatory Affairs
Health Canada's new terms and conditions framework takes effect April 1, 2027, replacing the NOC/c pathway. A practical guide to agile licensing and lifecycle obligations for sponsors.
#Health Canada
By Mussarat Fatima
June 11, 2026 · Regulatory Affairs
Health Canada's April 2026 pre-market guidance for machine learning-enabled medical devices introduces the Predetermined Change Control Plan (PCCP). Here is what Canadian manufacturers need to know about data quality, bias management and licensing.
#Health Canada
By Mussarat Fatima
June 11, 2026 · Regulatory Affairs
The biggest rewrite of EU GMP Annex 11 since 2011 lands mid-2026: 17 chapters covering validation, audit trails, supplier oversight, cybersecurity and a new Annex 22 on AI. Here is the gap assessment roadmap for Canadian exporters to the EU.
#Compliance
By Mussarat Fatima
June 10, 2026 · Regulatory Affairs
The revised EU-GMP Chapter 4 is format-neutral: photos, video and real-time feeds now count as GMP records. Learn what data-integrity controls your site needs before mid-2026.
#Pharmaceuticals
By Mussarat Fatima
June 9, 2026 · Regulatory Affairs
The FDA's 2026 CDER agenda adds guidance on distributed manufacturing, AI/ML quality, PET drug CGMP, and Form 483 responses. Here is what Canadian exporters should do now.
#Pharmaceuticals
By Mussarat Fatima
June 8, 2026 · Regulatory Affairs
How psychedelic-assisted therapy is regulated in Canada in 2025: the three legal pathways (clinical trials, the Special Access Program, and Section 56 exemptions), the controlled-substance rules for psilocybin and MDMA, and what the Toth v. Canada Federal Court ruling means for practitioner training.
#Health Canada
By Mussarat Fatima
June 7, 2026 · Regulations
Health Canada is consulting on major reforms to the Industrial Hemp Regulations, including possibly dropping licence requirements for some activities. Comments close June 30, 2026. Here is what is proposed, who benefits, and how to write a submission that gets read.
#Cannabis
By Mussarat Fatima
June 5, 2026 · Regulatory Affairs
From April 2026, Canadian cosmetics can no longer hide key fragrance allergens behind the word "parfum." A practical roadmap: what changed, how to read supplier allergen certificates, updating labels and CNFs, and what the 2026 Hotlist proposals mean for your formulas.
#Health Canada
By Mussarat Fatima
June 3, 2026 · Regulatory Affairs
By 2026, EU GMP Annex 1 is fully in force and firmly enforced. Any Canadian pharmaceutical manufacturer or cannabis Licensed Producer exporting sterile or EU-GMP product to the EU or UK must have a documented, living Contamination Control Strategy (CCS) ready for inspection—or risk critical findings and loss of market access.
#Health Canada
By Mussarat Fatima
June 2, 2026 · Regulations
Cannabis excise tax reform in Canada is gaining momentum. The Expert Panel's final report urged a review of the $1/gram excise floor and potency-based duties, a 2025 Deloitte report sharpened the case, and micro-class limits have already quadrupled. Here's what could change for licensed producers and how to prepare.
#Cannabis
By Mussarat Fatima
June 1, 2026 · Regulatory Affairs
ICH E6(R3) Good Clinical Practice has been in force in Canada since 1 April 2026, with the transition period closing 30 September 2026. A verified quality-by-design and risk-proportionality readiness plan for sponsors, CROs, and sites.
#Health Canada
By Mussarat Fatima
May 24, 2026 · Regulatory Affairs
Health Canada's April 2026 Final Notice (following its 14 August 2025 consultation Notice) clarifies how exosome, extracellular vesicle, and cell-conditioned media topical products are classified at the cosmetic-drug interface. Learn the three statutory considerations, MFLRC's six-trigger framework, the cosmetic/NHP/drug/biologic decision tree, and a reformulation checklist for skin-care, hair-care, and medi-aesthetic brands.
#Exosomes
By Mussarat Fatima
May 21, 2026 · Food and Beverages
As of January 1, 2026, Health Canada’s Front-of-Package (FOP) nutrition symbol is mandatory on prepackaged foods and beverages that are high in saturated fat, sugars, or sodium. Learn what the new rules require, who must comply, key exemptions, and how to complete a defensible FOP readiness assessment for your full SKU portfolio.
#FOP Nutrition Labelling
By Mussarat Fatima
May 20, 2026 · Natural Health Products
Health Canada's new NHP GMP Guide (GUI-0158, Version 4.0) came into force on March 4, 2026. It introduces real-time stability expectations, evidenced importer oversight, and a full quality-systems approach. Here is what Canadian NHP licence holders need to do now to stay inspection-ready.
#GUI-0158
By Mussarat Fatima
May 11, 2026 · Medical Device
EUDAMED is no longer optional. From 28 May 2026, the first four modules become mandatory for every economic operator selling devices into the EU. Here's the pre-flight checklist MDEL holders and EU manufacturers should already be running.
#EUDAMED
By Mussarat Fatima
May 8, 2026 · Compliance
The DEA's April 28 Schedule III order reshapes cross-border cannabis. Canadian LPs: here's what 280E elimination, M&A, and the June 27 deadline mean for your quality system — and your next capital raise.
#DEA, Schedule III, 280E, Canadian LP, Quality Systems, Cannabis M&A, Health Canada, GMP, Pharmaceutical Validation, Regulatory Affairs
By Mussarat Fatima
May 5, 2026 · Compliance
Learn how to comply with Health Canada’s 2026 cannabis sampling guidance, including storage, security, record-keeping, and provincial rules for retailer samples.
By Mussarat Fatima
March 29, 2026 · Regulations
Discover how new cannabis regulations in Canada simplify compliance for licence holders, boost competition, and enhance the market—find out more!
By Mussarat Fatima
March 29, 2026 · Compliance
Learn how cannabis licensing consultants can help Canadian cannabis businesses streamline compliance with expert knowledge, comprehensive SOPs, audits, tracking and reporting systems, and more. Get insights from industry experts and stay ahead of changing regulations.
By Mussarat Fatima
March 19, 2026 · Cannabis regulations, label, Quality assurance,
By Mussarat Fatima
February 11, 2026 · Compliance
The business case for food safety: what recalls and food fraud actually cost in Canada, how CFIA enforcement escalates, and why prevention is the cheapest insurance.
#Food Fraud
By Mussarat Fatima
February 2, 2026 · Compliance
A practical, up-to-date guide to Canada's micro-cultivation, micro-processing and nursery cannabis licences, including the 2025 limit increases, the CTLS application process and the compliance obligations that follow.
#Cannabis
By Mussarat Fatima
December 8, 2025 · Good Production Practices
Good Production Practices (GPP) are the legal foundation of every federal cannabis licence in Canada. This guide explains the Part 5 requirements, the QAP role, GPP versus EU-GMP, and how to stay inspection-ready.
#Good Production Practices
By Mussarat Fatima
November 4, 2025 · License
A practical guide to cannabis retail licensing in Canada, using Ontario as the worked example: the operator licence, store authorization, manager licence, CannSell training, eligibility, fees and compliance, with a national snapshot.
#Cannabis
By Mussarat Fatima
October 10, 2025 · Food and Beverages
Safe food handling is not a poster on the wall. Under the Safe Food for Canadians Regulations it is a set of enforceable controls across receiving, storage, temperature, hygiene and sanitation, each of which must be documented and provable at inspection.
#Food and Beverages
By Mussarat Fatima
October 7, 2025 · Compliance
A practical guide to what food safety services cover under Canada's Safe Food for Canadians Regulations: licensing, preventive control plans, traceability, and HACCP.
#Safe Food for Canadians
By Mussarat Fatima
October 3, 2025 · Compliance
Quality assurance is the system that makes pharmaceutical quality repeatable. Here is what QA really covers, how ICH Q10 and GMP fit together, and why it protects both patients and your licence.
#Pharmaceuticals
By Mussarat Fatima
September 30, 2025 · Compliance
A first grower's guide to trimming cannabis at the right time, from vegetative pruning to post-harvest, with the compliance steps licensed producers need.
#Cannabis
By Mussarat Fatima
September 26, 2025 · Compliance
Compliance keeps your licence, quality assurance keeps your product safe, and accreditation builds market trust. Here is how the three differ and why regulated health organizations need all three working together.
#Quality Management System
By Mussarat Fatima
September 23, 2025 · Quality Assurance
Process, product, system and people. The four types of quality assurance are a useful teaching model, not a legal classification. Here is what each one means, how Canadian regulators actually inspect it, and the more authoritative four that ICH Q10 defines.
#Quality Management System
By Mussarat Fatima
September 19, 2025 · Compliance
Compliance is not the same as quality. In Canadian regulated manufacturing, compliance is the documented proof that you controlled the process. Here is what that means in practice, how Health Canada grades it, and how to build a record that holds up.
#Compliance
By Mussarat Fatima
August 28, 2025 · Compliance
Health Canada issued 37 non-compliant inspection reports to cannabis licence holders in 2024 to 2025. The findings were not exotic. Here are the ten mistakes behind most of them, and the corrective actions that close them for good.
#Compliance
By Mussarat Fatima
August 25, 2025 · Compliance
Getting licensed is the start, not the finish. This guide sets out every obligation that begins the day your cannabis licence is issued, with the deadlines, the regulatory hooks and the systems that keep your authorization defensible.
#Compliance
By Mussarat Fatima
August 22, 2025 · GMP
There is no fixed audit schedule for cannabis companies in Canada. Health Canada inspects on a risk basis, and operators also face internal, EU-GMP, customer, and provincial audits. Here is what drives frequency and how to stay ready all year.
#Cannabis
By Mussarat Fatima
August 19, 2025 · Compliance
Natural health product and cannabis licences come from two separate federal frameworks. Here are the key differences in law, product authorisation, site and quality requirements, timelines, and compliance, so you can choose the right pathway.
#Natural Health Products
By Mussarat Fatima
August 13, 2025 · Compliance
A cannabis sales licence can mean a federal licence for sale or a provincial retail authorization. Here is what each costs, how long it takes, and how to stay compliant.
#Cannabis
By Mussarat Fatima
August 12, 2025 · Compliance
Opening a cannabis retail store in Canada means clearing two layers of rules: federal production law and provincial retail licensing. Here is the step-by-step path, the Ontario AGCO fee example, the real costs and a compliance checklist.
#Cannabis
By Mussarat Fatima
August 12, 2025 · Compliance
Health Canada issues two cannabis processing licence classes. Learn how standard and micro licences differ on production limits, cost, compliance and market reach, and how to choose the right one under the current 2,400 kg micro limit.
#Cannabis
By Mussarat Fatima
August 12, 2025 · Compliance
Advertising a cannabis business means working within strict promotion rules. This guide covers the Cannabis Act limits, compliant channels, CASL, US state restrictions, and the mistakes that lead to penalties.
By Mussarat Fatima
August 12, 2025 · Compliance
Cannabis cultivation in Canada is a licensed, science-driven activity. This guide covers licence classes, the 2025 micro-limit changes, Good Production Practices, facility design, and the quality systems Health Canada expects to see.
By Mussarat Fatima
August 12, 2025 · License
Farmgate stores let licensed producers sell cannabis at their own facilities. Here is how farmgate licensing works in Canada and why it is a powerful tool for small and micro growers.
#Cannabis
By Mussarat Fatima
August 7, 2025 · Regulatory Affairs
A regulatory dossier is the organized evidence that turns a product into an approved product. Learn what a dossier is, the main types across pharma, cannabis, NHP, food, cosmetics and devices, and how to prepare one.
#Compliance
By Mussarat Fatima
June 21, 2025 · GMP
Selling cannabis legally in Canada takes more than one licence. This guide maps the Health Canada licence classes, the CRA excise layer, provincial retail rules and the daily compliance obligations that keep a licence alive.
#Cannabis
By Mussarat Fatima
June 18, 2025 · License
Farmgate and retail cannabis licences follow very different rules in Canada. This guide explains who can apply, how Ontario, British Columbia and Alberta structure their programs, and what compliance looks like after opening.
#Cannabis
By Mussarat Fatima
June 15, 2025 · Good Production Practices
A step-by-step guide to building a compliant cannabis analytical testing lab in Canada, from the licence for analytical testing and head of laboratory to validated methods, equipment, and ISO/IEC 17025 accreditation.
#Analytical Testing
By Mussarat Fatima
June 12, 2025 · Good Production Practices
Build a cannabis QA compliance checklist that satisfies Health Canada Good Production Practices, from QAP oversight and mandatory testing to recalls and inspection readiness.
#Cannabis
By Mussarat Fatima
June 9, 2025 · License
Cannabis retail rules change at every provincial border. A senior consultant's guide to how provincial cannabis licences differ across Canada and how to plan for multi-province expansion.
#Cannabis
By Mussarat Fatima
June 6, 2025 · License
A senior consultant's guide to the cannabis licence application mistakes that stall Health Canada approval, and how to build a CTLS submission that clears review the first time.
#Cannabis
By Mussarat Fatima
June 3, 2025 · Compliance
A Health Canada inspection rewards everyday discipline, not last-minute cramming. Here is what inspectors check, the findings that trip producers up, and how to stay audit-ready every day.
#Cannabis
By Mussarat Fatima
September 25, 2024 · GMP
In Canada, cannabis producers follow Good Production Practices, while EU-GMP certification unlocks export markets like Germany. Here is what GMP certification involves, what it costs, and how to prepare.
#Cannabis
By Mussarat Fatima
July 2, 2024 · Compliance
Cannabis legalisation opened a retail opportunity across Canada, but a dispensary is not what most people think, and you do not get a store licence from Health Canada. Here is how the federal and provincial systems fit together, and the steps to open a legal cannabis store.
#Cannabis
By Mussarat Fatima
December 19, 2023 · License
A cannabis research licence is how universities, companies and clinicians legally study cannabis in Canada. This guide explains the licence types, the CTLS application process, NTRC and clinical-trial rules, and how to build an approvable file.
#Cannabis Research
By Mussarat Fatima
October 17, 2023 · Cultivation
Five years after Canada legalized cannabis in October 2018, we review the achievements and the ongoing challenges, from economic growth and public health to youth use, impaired driving and pricing.
#Cannabis
By Mussarat Fatima
March 23, 2023 · Compliance
Quality assurance is not optional for Canadian cannabis licence holders. Here is what QA involves under current Health Canada rules, the real risks of cutting corners, and a practical compliance checklist.
#Cannabis
By Mussarat Fatima
October 5, 2022 · Good Production Practices
Root cause analysis drives effective CAPA. Learn the 11 mistakes that make investigations fail in cannabis and GMP facilities, and how to avoid each one.
#Cannabis
By Mussarat Fatima
September 9, 2022 · Good Production Practices
Cannabis recalls are preventable quality failures. Here are nine practical ways to avoid them, plus Health Canada recall types, timelines, and mock recall rules.
#Cannabis
By Mussarat Fatima
September 9, 2022 · License
A practical, up to date guide to opening and operating a cannabis retail store or farmgate in Ontario, covering AGCO licences, OCS wholesale, store rules, fees, staff training and the compliance habits that keep your authorization in good standing.
#Cannabis
By Mussarat Fatima
September 8, 2022 · Compliance
Ten practical essentials for cannabis compliance in Canada, from building a compliance team and internal audits to marketing rules, provincial age limits and recordkeeping.
#Cannabis
By Mussarat Fatima
September 8, 2022 · Compliance
Internal audits help Canadian cannabis, pharma and NHP producers find and fix compliance gaps before Health Canada does. Learn the process, checklist and best practices.
#Cannabis
By Mussarat Fatima
